Cibus vs Arcadia Biosciences
Arcadia Biosciences is the larger business, with $4.9m of revenue in fiscal 2025 against $3.6m for Cibus (1.3 times as much). Arcadia Biosciences grew faster (-3.7% against -14.6%). Arcadia Biosciences kept more of each dollar of sales as profit: a net margin of -48.1% against -3492.3%.
| Latest fiscal year | CibusCBUS, 2025 | Arcadia BiosciencesRKDA, 2025 |
|---|---|---|
| Revenue | $3.6m | $4.9m |
| Revenue growth | -14.6% | -3.7% |
| Net income | −$127m | −$2.3m |
| Operating margin | -2680.1% | — |
| Net margin | -3492.3% | -48.1% |
| Return on equity | — | -45.1% |
| Free cash flow | −$51.2m | −$4.7m |
| Cash | $9.9m | $259,000 |
| Total debt | $559,000 | $0 |
| Debt to equity | 2.6% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $86.7m | $338,384 |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | 14 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |